Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Dermata Therapeutics, Inc. (DRMA) had Stock-Based Compensation of $0.04M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-2.30M |
|
-- |
|
-- |
|
$2.34M |
|
$-2.34M |
|
$0.04M |
|
$-2.30M |
|
$-2.30M |
|
$-2.30M |
|
$-2.30M |
|
$-2.30M |
|
$-2.30M |
|
$-2.34M |
|
$-2.34M |
|
5.15M |
|
5.15M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$10.01M |
|
-- |
|
-- |
|
$10.01M |
|
$2.70M |
|
-- |
|
-- |
|
$2.70M |
|
$7.30M |
|
$7.30M |
|
$7.30M |
|
6.03M |
|
| Cash Flow Statement Financials | |
$-1.93M |
|
-- |
|
$8.49M |
|
$3.16M |
|
$9.72M |
|
$6.56M |
|
|
Stock-Based Compensation |
$0.04M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.93M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.55% |
|
-31.55% |
|
-23.02% |
|
-31.55% |
|
$1.21 |
|
$-0.38 |
|
$-0.38 |
|